Alembic Pharmaceuticals on Friday said that it has received Establishment Inspection Report (EIR) from the US Food & Drug Administration (USFDA) for its formulations facility at Panelav, Gujarat. The inspection was carried out by the regulator during October 22 and 25, 2018. Shares of Alembic Pharmaceuticals ended flat at ₹ 538.15 on the BSE.
Company news: Alembic Pharmaceuticals
Published on
April 5, 2019 15:51